Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02918006 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine
A Phase 2 study of Influenza, sponsored by Vaxart.
- Completed
- Registry status
- Phase 2
- Development phase
- 179
- Enrollment target
- 1
- Study location
NCT02918006: Completed Phase 2 study of Influenza, sponsored by Vaxart.
NCT02918006 is a Phase 2 study of Influenza that has completed, run by Vaxart. The registered enrollment target is 179 participants, below the 36,803-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02918006, a Phase 2 study of Influenza, has completed, sponsored by Vaxart.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 179 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 2 Randomized, Placebo- and Active-Controlled, Human Influenza A/California/04/2009 (H1N1) Challenge Study Following Administration of an Oral H1N1 Hemagglutinin (HA) Adenoviral-Vector Based Seasonal Influenza Vaccine and dsRNA Adjuvant (VXA-A1.1) to Healthy Adult Volunteers.
Primary Outcome
The clinical efficacy of VXA-A1.1 to protect against illness caused by the homologous A strain influenza virus with challenge 3 months following a single immunization in comparison to placebo and QIV. Participants were evaluated for clinical signs and symptoms of influenza as well as for viral shedding via PCR for confirmation of infection.
Conditions Studied
Interventions
- OTHER Placebo Tablets
- BIOLOGICAL Fluzone®
- BIOLOGICAL VXA-A1.1
- OTHER Saline Solution for Placebo IM Injection
Study Locations (1)
California
- WCCT Global - Costa Mesa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2016-08-31 |
| Est. Completion | 2018-01-19 |
| Phase | Phase 2 |
What the finished NCT02918006 record still lists
NCT02918006 is an interventional study that assigns participants to a tested intervention. The registered 179 participants enrollment target is mid-sized for trials with a published cap, below the 36,803-participant average among 156 other Influenza trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 4 interventions - of which Placebo Tablets is the first listed.
NCT02918006 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02918006 about?
NCT02918006 is a clinical study titled "A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine". A Phase 2 Randomized, Placebo- and Active-Controlled, Human Influenza A/California/04/2009 (H1N1) Challenge Study Following Administration of an Oral H1N1 Hemagglutinin (HA) Adenoviral-Vector Based Seasonal Influenza Vaccine and dsRNA Adjuvant (VXA-A1.1) to Healthy Adult Volunteers.
What is the current status of trial NCT02918006?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 179 participants. The study started on 2016-08-31. Estimated completion is 2018-01-19.
What conditions does trial NCT02918006 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT02918006?
The interventions under investigation include: Placebo Tablets (OTHER), Fluzone® (BIOLOGICAL), VXA-A1.1 (BIOLOGICAL), Saline Solution for Placebo IM Injection (OTHER).
Who is sponsoring clinical trial NCT02918006?
This trial is sponsored by Vaxart, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02918006 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02918006's enrollment target sits among peer trials
179 86th of 156 higher than 71 of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)
RECRUITING · Phase 2
-
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
RECRUITING · Phase 2
-
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
RECRUITING · Phase 2
-
Systems Investigation of Vaccine Responses in Aging and Frailty
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06581198 · 179 participants · Phase 2
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
- NCT07356323 · 179 participants · NA
A Prospective, Single-arm, Trial to Determine Contamination Rates When Using an Antibacterial Incise Drape During Orthopedic Surgery
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI